MAIA MAIA Biotechnology Inc

$MAIA *yawn* Shorts out here trying to make people panic. Boring. There's are well-known catalysts on the horizon. No one is worried if it drifts between now or then but day traders. Save your FUD for someone else.

$MAIA I am quite bullish on $MAIA, even though the SP is disappointing at the moment. Even though the $2.3M from National Institutes of Health (NIH) don't seem much, but it is a huge achievement: Obtaining federal funding for clinical-stage biotech trials is competitive and requires rigorous peer-review panels composed of top independent oncologists and scientists. The award of a $2.3 million NIH grant to fund the U.S. Phase 2 expansion sites serves as a strong peer-reviewed validation of THIO's underlying biology and clinical rationale.

$MAIA $OSTX I'm primary MAIA but bought a bag of OSTX on great news and (Odd) dip at 1.68 . the OSTX news this morning is genuinely strong clinical news. This isn't just a conference announcement or corporate update. The final Phase 2b 3-year overall-survival results for Herlystic (OST-HER2) were: - 72.7% alive at 3 years with Herlystic - 45.8% in the comparable historical-control group - p = 0.0006, which is highly statistically significant - 41 patients were enrolled; four were lost to follow-up. Stock Titan And there's an important improvement from the September interim analysis. That earlier result was 71.2% vs. 45.8%, p=0.002. The final analysis moved survival up to 72.7% and strengthened the statistical significance to p=0.0006.

$MAIA just received regulatory approval to begin screening in Spain and Portugal for its pivotal Phase 3 THIO-104 lung-cancer trial.

$MAIA I've always said that the Face-centered Cubic Carbon Dog shouldn't invest in this stock. He hasn't even read a high school textbook, let alone Janeway's... he just panics out, because he doesn't understand how big and unique the MOA is. And he also needs to read a basic book on investing. Trying to claim that insiders throw their money away by buying stock that they know will go down is not supported by any statistical study. CFO buys are the best, but even the lowly CEOs still predict stock outperformance. Go back to telling people to sell CADL in the 9s right before the biomarker data comes out, Dog... you and Stu4 have a great record over there 🤣📉📉📉

$MAIA About 5 weeks away from the Prix Galean Awards, then JPMHCC is coming in January. MAIA has more than enough cash to make it into Q2/Q3 2027. Current share price is a tasty buying opportunity 💰

$MAIA A simple projection is interesting: 65 now → >100 by Dec. 31 requires only ~35 additional patients over ~100 days. That's roughly 10–11 patients/month. Their increase from June to September has been roughly that pace already. So 100+ by year-end looks quite achievable if the current enrollment rate continues. It doesn't require a major acceleration.

$MAIA Let's test your GENIUS 1. You begged people to buy at 3.50 during Phase 2 and before Phase 2 2. You begged people to sell when it later dropped below 1.00 3. You said MAIA would never get money without warrants and later they got 33M without warrants 3. You think 33M and 2.3 million is nothing and doesn't help Please tell me your a PAID TROLL and if not, your making a fool of yourself for NOTHING. Genius, what are your 3 top positions?

$MAIA So your saying Merck isnt worried about it's 30 B patent cliff especially after losing Europe this week with court ruling.

$MAIA It's definitely possible for MAIA to penetrate the 3L NSCLC market and get widely adopted quickly, especially with a commercial partner like Regeneron that already has the infrastructure set up to sell both Libtayo and Cemiplimab in combination. $150K selling price is also a good guess on what the selling price will be. $150k x 10,000 is $1.5B annually in sales at 20% market penetration in the US market. Since ateganosine is a small molecule, the COGS will be low and free cash flow will be abundant. Could we hit 90% market penetration like says? Probably, but even if we hit half that, we'll be on a rocket ship to $10B market cap. Lung cancer trials are dropping like flies, which will make MAIA stand out even more with a great interim readout. Visibility is going to be huge at the Prix Galean 🥂

$MAIA Skin in the game is a big deal for me. Some might say, bloated salaries make it easy…..but even if, they could find a million other ways to spend if they didn’t believe in what they’re doing. Not worried. Loaded.

$MAIA It's October. The Prix Galean is in exactly 4 weeks 🥂 We'll be fully visible to all top decision-makers in Pharma 💰🪙

$MAIA If the 90% DCR holds, this will be fantastic for all patients currently on 3rd line NSCLC treatment.

$MAIA reached 65 patients in its pivotal Phase 3 NSCLC trial, keeping on track for 100 by year-end.

$MAIA TAM is 85% of all cancers. And MAIA has the only drugs that kill telomerase-positive dividing cells. We may end up in Arkham for a while, but it's hard to believe that this won't ramp up after Phase 3 interim results.

$MAIA Not looking good. Bond rates at 25 year highs. Credit crunch in place and it doesn't go well for companies that need cash. Don't expect big Pharma to hand out licensing deals. They are notorious for being cautious in uncertain times. And if they hand out any deals, the terms will be bad. For all those with small cap stocks: hang on to your hats. This will be hairy.

$MAIA Another failed Lung Cancer trial ….ArriVent BioPharma (AVBP) shares crashed over 48% to an all-time low on October 6, 2026, after its Phase 3 FURVENT trial for lung cancer treatment failed to meet its primary endpoint. 📉 Trial Setback • Failed Endpoint: Firmonertinib missed progression-free survival in non-small cell lung cancer. • Market Impact: Stock plunged over 48% to a record low near $12.09. • Response Rate: Showed a 60% confirmed response rate versus 33% for chemotherapy.

$MAIA This stock has $100+ written all over it if THIO 104 is a success. Do what you want, but I’m taking my odds to the bank and loading up on shares.

$MAIA …9/16:today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation and MAIA has activated 3 sites in the U.S.

$MAIA MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO